{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:01:22Z","timestamp":1785520882732,"version":"3.56.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jceh.2023.03.011","type":"journal-article","created":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T11:21:11Z","timestamp":1680348071000},"page":"869-877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug Interactions and Safe Prescription Writing for Liver Transplant Recipients"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1590-999X","authenticated-orcid":false,"given":"Johns S.","family":"Mathew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9587-336X","authenticated-orcid":false,"given":"Cyriac A.","family":"Philips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2023.03.011_bib1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00000658-196809000-00009","article-title":"Orthotopic homotransplantation of the human liver","volume":"168","author":"Starzl","year":"1968","journal-title":"Ann Surg"},{"key":"10.1016\/j.jceh.2023.03.011_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/hep.1840040717","article-title":"Orthotopic liver transplantation in Groningen, The Netherlands (1979\u20131983)","volume":"4","author":"Krom","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2023.03.011_bib3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJM198107303050507","article-title":"Liver transplantation with use of cyclosporin A and prednisone","volume":"305","author":"Starzl","year":"1981","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2023.03.011_bib4","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJM199410273311702","article-title":"A\u00a0comparison of Tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation","volume":"331","author":"Group","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2023.03.011_bib5","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(02)11196-2","article-title":"Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial","volume":"360","author":"O'grady","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2023.03.011_bib6","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(95)92534-1","article-title":"Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection","volume":"345","author":"Group","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2023.03.011_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00007890-199508000-00003","article-title":"Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group","volume":"60","author":"Sollinger","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2023.03.011_bib8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00007890-199604150-00008","article-title":"A\u00a0blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation","volume":"61","author":"Keown","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2023.03.011_bib9","doi-asserted-by":"crossref","unstructured":"Levy G, Schmidli H, Punch JD, et\u00a0al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12-and 36-month results Presented at the American Transplant Congress in Boston, MA, May 15-19, 2004 (abstracts 250461 and 251150). 2006.","DOI":"10.1002\/lt.20707"},{"key":"10.1016\/j.jceh.2023.03.011_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1600-6143.2005.00748.x","article-title":"Pharmacokinetic principles of immunosuppressive drugs","volume":"5","author":"Srinivas","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jceh.2023.03.011_bib11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.bbmt.2011.11.029","article-title":"Important drug interactions in hematopoietic stem cell transplantation: what every physician should know","volume":"18","author":"Glotzbecker","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jceh.2023.03.011_bib12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","article-title":"Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and Tacrolimus","volume":"74","author":"Hesselink","year":"2003","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jceh.2023.03.011_bib13","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.4254\/wjh.v7.i10.1355","article-title":"Review on immunosuppression in liver transplantation","volume":"7","author":"Moini","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jceh.2023.03.011_bib14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/ajt.16494","article-title":"OPTN\/SRTR 2019 annual data report: liver","volume":"21","author":"Kwong","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jceh.2023.03.011_bib15","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.hpb.2020.09.012","article-title":"Randomized trial of steroid free immunosuppression with basiliximab induction in adult live donor liver transplantation (LDLT)","volume":"23","author":"Kathirvel","year":"2021","journal-title":"HPB"},{"key":"10.1016\/j.jceh.2023.03.011_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.1993.tb17137.x","article-title":"The mechanism of action of FK-506 and cyclosporin A","volume":"696","author":"Wiederrecht","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jceh.2023.03.011_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Therapeut"},{"key":"10.1016\/j.jceh.2023.03.011_bib18","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1067\/mcp.2001.115142","article-title":"Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation","volume":"69","author":"Hashida","year":"2001","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jceh.2023.03.011_bib19","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/S0021-9258(18)53221-X","article-title":"Human P-glycoprotein transports cyclosporin A and FK506","volume":"268","author":"Saeki","year":"1993","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jceh.2023.03.011_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cld.2016.08.011","article-title":"Drug metabolism, drug interactions, and drug-induced liver injury in living donor liver transplant patients","volume":"21","author":"Ganesh","year":"2017","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2023.03.011_bib21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00007691-199902000-00006","article-title":"Evidence that Tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation","volume":"21","author":"Zucker","year":"1999","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jceh.2023.03.011_bib22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1046\/j.1600-6143.2005.00779.x","article-title":"Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2","volume":"5","author":"Hesselink","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jceh.2023.03.011_bib23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/clpt.2010.320","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing","volume":"89","author":"Relling","year":"2011","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jceh.2023.03.011_bib24","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MNH.0b013e32832edcb2","article-title":"Drug interactions in transplant patients: what everyone should know","volume":"18","author":"Manitpisitkul","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jceh.2023.03.011_bib25","series-title":"Prograf (Tacrolimus) [prescribing Information]","year":"2015"},{"key":"10.1016\/j.jceh.2023.03.011_bib26","series-title":"Envarsus XR (Tacrolimus) [prescribing Information]","year":"2015"},{"key":"10.1016\/j.jceh.2023.03.011_bib27","series-title":"Astagraf XL (Tacrolimus) [prescribing Information]","year":"2020"},{"key":"10.1016\/j.jceh.2023.03.011_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13833","article-title":"Signal of safety due to adverse drug reactions induced by Tacrolimus with or without azithromycin","author":"Yonezawa","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jceh.2023.03.011_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13510","article-title":"Interactions between anti-infective agents and immunosuppressants\u2014guidelines from the American society of transplantation infectious diseases community of practice","volume":"33","author":"Sparkes","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jceh.2023.03.011_bib30","series-title":"Zortress (Everolimus) [prescribing Information]","year":"2018"},{"key":"10.1016\/j.jceh.2023.03.011_bib31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00007890-199808270-00021","article-title":"QT prolongation and near fatal cardiac arrhythmia after intravenous Tacrolimus administration: a case report","volume":"66","author":"Hodak","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2023.03.011_bib32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/00003088-200645020-00003","article-title":"Pharmacokinetic interaction between levofloxacin and ciclosporin or Tacrolimus in kidney transplant recipients","volume":"45","author":"Federico","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jceh.2023.03.011_bib33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/FTD.0b013e31803111d5","article-title":"The magnitude and time course of changes in mycophenolic acid 12-hour predose levels during antibiotic therapy in mycophenolate mofetil-based renal transplantation","volume":"29","author":"Borrows","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jceh.2023.03.011_bib34","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/01.ftd.0000167885.17280.6f","article-title":"Determinants of mycophenolic acid levels after renal transplantation","volume":"27","author":"Borrows","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jceh.2023.03.011_bib35","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1399-3062.2012.00721.x","article-title":"Tacrolimus as a risk factor for tuberculosis and outcome of treatment with rifampicin in solid organ transplant recipients","volume":"14","author":"Ha","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jceh.2023.03.011_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1345\/aph.19069","article-title":"Renal allograft dysfunction associated with rifampin\u2013Tacrolimus interaction","volume":"34","author":"Chenhsu","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jceh.2023.03.011_bib37","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1345\/aph.1A384","article-title":"Effect of rifampin on apparent clearance of everolimus","volume":"36","author":"Kovarik","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jceh.2023.03.011_bib38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/00912709922007499","article-title":"Effects of rifampin on Tacrolimus pharmacokinetics in healthy volunteers","volume":"39","author":"Hebert","year":"1999","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jceh.2023.03.011_bib39","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clpt.2006.08.002","article-title":"Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients","volume":"80","author":"Naesens","year":"2006","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jceh.2023.03.011_bib40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/0971-4065.62091","article-title":"Mycophenolic acid area under the curve recovery time following rifampicin withdrawal","volume":"20","author":"Annapandian","year":"2010","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.jceh.2023.03.011_bib41","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00007890-198608000-00023","article-title":"Severe nephrotoxicity caused by the combined use of gentamicin and cyclosporine in renal allograft recipients","volume":"42","author":"Termeer","year":"1986","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2023.03.011_bib42","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Br\u00fcggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jceh.2023.03.011_bib43","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/01.TP.0000121133.84763.26","article-title":"A\u00a0prospective, randomized study of coadministration of ketoconazole and cyclosporine a in kidney transplant recipients: ten-year follow-up","volume":"77","author":"El-Agroudy","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2023.03.011_bib44","series-title":"Transplantation Proceedings","article-title":"Everolimus versus azathioprine in a cyclosporine and ketoconazole\u2013based immunosuppressive therapy in kidney transplant: 3-year follow-up of an open-label, prospective, cohort, comparative clinical trial","year":"2010"},{"key":"10.1016\/j.jceh.2023.03.011_bib45","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/00007890-199405270-00022","article-title":"Fluconazole therapy in transplant recipients receiving FK506","volume":"57","author":"Ma\u00f1ez","year":"1994","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2023.03.011_bib46","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1016\/j.ijid.2009.04.012","article-title":"Voriconazole inhibition of Tacrolimus metabolism in a kidney transplant recipient with fluconazole-resistant cryptococcal meningitis","volume":"14","author":"Chang","year":"2010","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jceh.2023.03.011_bib47","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1086\/374252","article-title":"Voriconazole inhibition of Tacrolimus metabolism","author":"Pai","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jceh.2023.03.011_bib48","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cpdd.284","article-title":"Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and Tacrolimus in healthy adults","volume":"6","author":"Groll","year":"2017","journal-title":"Clin Pharma Drug Develop"},{"key":"10.1016\/j.jceh.2023.03.011_bib49","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/2047-783X-16-4-159","article-title":"Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis-review of the literature","volume":"16","author":"Kofla","year":"2011","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.jceh.2023.03.011_bib50","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1399-3062.2004.00065.x","article-title":"Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A","volume":"6","author":"Marr","year":"2004","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jceh.2023.03.011_bib51","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1177\/106002809603000521","article-title":"Tacrolimus\u2014phenytoin interaction","volume":"30","author":"Thompson","year":"1996","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jceh.2023.03.011_bib52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00007691-200302000-00019","article-title":"Phenytoin decreases the blood concentrations of sirolimus in a liver transplant recipient: a case report","volume":"25","author":"Fridell","year":"2003","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jceh.2023.03.011_bib53","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1177\/1060028014546184","article-title":"Rapid resolution of Tacrolimus intoxication\u2013induced AKI with a corticosteroid and phenytoin","volume":"48","author":"Bax","year":"2014","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jceh.2023.03.011_bib54","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.hemonc.2015.11.001","article-title":"Clotrimazole troches induce supratherapeutic blood levels of sirolimus and Tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury","volume":"9","author":"El-Asmar","year":"2016","journal-title":"Hematology\/Oncology Stem Cell Therapy"},{"key":"10.1016\/j.jceh.2023.03.011_bib55","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/ajt.13826","article-title":"Combination drug products for HIV\u2014a word of caution for the transplant clinician","volume":"16","author":"Patel","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jceh.2023.03.011_bib56","article-title":"Treatment of acute Tacrolimus toxicity with phenytoin in solid organ transplant recipients","volume":"2013","author":"Jantz","year":"2013","journal-title":"Case Reports Transplant"},{"key":"10.1016\/j.jceh.2023.03.011_bib57","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/01.TP.0000158738.00927.65","article-title":"Mechanisms of hypertension after liver transplantation","volume":"79","author":"Neal","year":"2005","journal-title":"Transplantation"},{"issue":"6 suppl l","key":"10.1016\/j.jceh.2023.03.011_bib58","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/00007890-200109271-00004","article-title":"Mechanisms and consequences of arterial hypertension after renal transplantation","volume":"72","author":"Koomans","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2023.03.011_bib59","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1211\/jpp.59.10.0008","article-title":"Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport","volume":"59","author":"Amioka","year":"2007","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.jceh.2023.03.011_bib60","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00003088-200241050-00005","article-title":"Pharmacokinetic interaction between Tacrolimus and diltiazem","volume":"41","author":"Jones","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jceh.2023.03.011_bib61","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1067\/mcp.2001.112513","article-title":"Pharmacokinetic interaction between single oral doses of ditiazem and sirolimus in healthy volunteers","volume":"69","author":"B\u00f6ttiger","year":"2001","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jceh.2023.03.011_bib62","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2133\/dmpk.DMPK-12-RG-148","article-title":"Effect of CYP3A5\u2217 3 polymorphism on pharmacokinetic drug interaction between Tacrolimus and amlodipine","volume":"28","author":"Zuo","year":"2013","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.jceh.2023.03.011_bib63","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MOT.0000000000000198","article-title":"New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease","volume":"20","author":"Kwo","year":"2015","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.jceh.2023.03.011_bib64","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/TP.0000000000001414","article-title":"Successful treatment of chronic hepatitis C virus infection with sofosbuvir and ledipasvir in renal transplant recipients","volume":"101","author":"Eisenberger","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2023.03.011_bib65","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2165\/00003088-200746110-00002","article-title":"Effect of highly active antiretroviral therapy on Tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study","volume":"46","author":"Teicher","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jceh.2023.03.011_bib66","series-title":"Foscavir (Foscarnet) [prescribing Information]","year":"2014"},{"key":"10.1016\/j.jceh.2023.03.011_bib67","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/rheumatology\/keq238","article-title":"Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil","volume":"49","author":"Schaier","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.jceh.2023.03.011_bib68","doi-asserted-by":"crossref","first-page":"E217","DOI":"10.1111\/j.1399-3046.2011.01559.x","article-title":"A\u00a0clinically significant interaction between Tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient","volume":"16","author":"Maguire","year":"2012","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jceh.2023.03.011_bib69","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3389\/fmed.2018.00320","article-title":"Pantoprazole does not affect serum trough levels of Tacrolimus and everolimus in liver transplant recipients","volume":"5","author":"Bremer","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.jceh.2023.03.011_bib70","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40264-022-01189-w","article-title":"Prevalence of use of traditional, complementary and alternative medicine by the general population: a systematic review of national studies published from 2010 to 2019","volume":"45","author":"Lee","year":"2022","journal-title":"Drug Saf"},{"key":"10.1016\/j.jceh.2023.03.011_bib71","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/11597910-000000000-00000","article-title":"Drug interactions with herbal medicines","volume":"51","author":"Shi","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jceh.2023.03.011_bib72","unstructured":"National Center for Complementary and Integrative Health. The NCCIH clinical digest on herb-drug interactions. Retrieved on 12th December 2022 from https:\/\/www.nccih.nih.gov\/health\/providers\/digest\/herb-drug-interactions."},{"key":"10.1016\/j.jceh.2023.03.011_bib73","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/hep4.1904","article-title":"Tinospora cordifolia (Giloy)-Induced liver injury during the COVID-19 pandemic-multicenter nationwide study from India","volume":"6","author":"Kulkarni","year":"2022","journal-title":"Hepatol Commun"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688323000567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688323000567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:09:38Z","timestamp":1760854178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688323000567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0973688323000567"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2023.03.011","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug Interactions and Safe Prescription Writing for Liver Transplant Recipients","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2023.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}